Home > Animal Health & Nutrition > Veterinary Pharmaceuticals > Companion Animal Arthritis Market

Companion Animal Arthritis Market - By Treatment Type (Medication [NSAIDs, mAbs], Food Supplement, Surgery), Disease Type (Osteoarthritis, Rheumatoid Arthritis), Animal Type (Dogs, Cats), End-use (Hospitals, Clinics)– Global Forecast 2024 – 2032

  • Report ID: GMI10785
  • Published Date: Aug 2024
  • Report Format: PDF

Companion Animal Arthritis Market Size

Companion Animal Arthritis Market size was valued at approximately USD 3.4 billion and is projected to grow at a CAGR of 7.2% from 2024 and 2032. Arthritis, a common ailment in companion animals like dogs and cats, involves inflammation and degradation of joint cartilage and the underlying bone. This condition results in pain, stiffness, and reduced mobility, severely affecting the quality of life for these pets. The rising incidence of arthritis in companion animals, especially in dogs and cats, mirrors broader trends in pet ownership, an aging demographic, and evolving lifestyle factors.
 

Companion Animal Arthritis Market

One of the primary drivers for the growth of the companion animal arthritis market is the increasing ownership of pets. This surge in pet ownership has led to a heightened demand for companion animal healthcare products, including medications and supplements. According to the National Pet Owners Survey by the American Pet Products Association, approximately 86.9 million American families, or 66%, own pets ranging from birds and cats to dogs and ferrets. Furthermore, the global increase in pet adoption, combined with technological advancements in veterinary medicine—such as enhanced diagnostic tools and more effective treatment options—bolsters market growth. These innovations not only enhance treatment efficacy but also broaden the spectrum of treatable conditions.
 

Companion Animal Arthritis Market Trends

Veterinary clinics are adopting advanced imaging techniques, including MRI (magnetic resonance imaging) and CT (computed tomography) scans, to diagnose joint conditions in pets. These state-of-the-art tools provide veterinarians with detailed insights into joint structures, enabling them to devise more accurate treatment plans.
 

  • The rising prevalence of arthritis in companion animals drives the demand for advanced diagnostic tools and effective treatment options.
     
  • For example, veterinary research indicates that nearly 90% of cats and 20% of dogs exhibit some form of arthritis, with the likelihood increasing with age. A significant number of pets over seven years old show arthritis symptoms.
     
  • Additionally, the introduction of innovative therapeutic technologies and devices, such as laser treatments, customized rehabilitation programs, and activity monitors, is propelling the market's growth.
     

Companion Animal Arthritis Market Analysis

Companion Animal Arthritis Market, By Treatment Type, 2021–2032 (USD Billion)

Based on treatment type, the market is segmented into medication, food supplement, surgery and other treatment types. The medication segment is further bifurcate into NSAIDs, monoclonal antibodies, and other medications. The medication segment is estimated to account for USD 1.5 billion in 2023.
 

  • Veterinarians prescribe pharmaceutical drugs, including NSAIDs, corticosteroids, and disease-modifying osteoarthritis drugs (DMOADs), to relieve arthritis symptoms in companion animals, focusing on pain relief and reducing inflammation. 
     
  • Advancements in veterinary medicine, such as better diagnostics, stronger medications, and comprehensive treatment protocols, improve the effectiveness and accessibility of arthritis treatments.
     
  • While medications currently dominate the market due to their effectiveness in managing symptoms, alternative therapies and regenerative medicines are becoming popular for promoting joint health and mobility in aging or arthritic pets.
     
  • The introduction of biologic therapies, such as monoclonal antibodies and stem cell treatments, has expanded treatment options for arthritis in companion animals, contributing to market growth.

 

Companion Animal Arthritis Market, By Disease Type (2023)

Based on disease type the companion animal arthritis market is segmented into osteoarthritis, rheumatoid arthritis, and other arthritis types. The osteoarthritis segment dominated the market with the market share of 64.3% in 2023.
 

  • Osteoarthritis, a common form of arthritis in pets, affects up to 20% of older dogs and cats, causing joint cartilage degeneration and bone changes.
     
  • The growing consumer preference for natural and holistic treatments, including nutraceuticals like glucosamine, chondroitin, and omega-3 fatty acids, is expected to increase the demand for products managing osteoarthritis in dogs, thereby driving market growth.
     

Based on animal type the companion animal arthritis market is segmented into dogs, cats, and other animals. The dogs’ segment is expected to reach USD 4.5 billion by 2032.
 

  • Older dogs and certain breeds, like Labrador Retrievers and German Shepherds, are particularly susceptible to arthritis.
     
  • As pet adoption rates climb, so do expenditures on pet healthcare supplies and services. Pet owners are increasingly investing in canine arthritis treatments, aiming to enhance their dogs' quality of life.
     
  • The market for animal arthritis therapies is witnessing swift expansion, with emerging trends hinting at new solutions to further elevate the quality of life for dogs, fueling the market's growth.
     

Based on end-use, the companion animal arthritis market is segmented into veterinary hospitals, veterinary clinics, veterinary rehabilitation centers, and other end-users. The veterinary hospitals segment is expected to exhibit 7.3% CAGR between 2024 – 2032.
 

  • Veterinary hospitals provide a wide range of services, including surgical procedures, physical therapy, and continuous monitoring of arthritis progression. Pet owners depend on veterinarians for expert guidance on managing arthritis, including treatment options and dosages.
     
  • As pet ownership rises due to companionship, health benefits, and lifestyle changes, the demand for veterinary services grows. This includes routine checkups, vaccinations, and treatments for conditions like arthritis. Increased visits to veterinary hospitals boost the demand for medications and therapies, driving market growth.

 

North America Companion Animal Arthritis Market, 2021–2032 (USD Billion)

In 2023, North America commanded a dominant 45.6% share of the global companion animal arthritis market, with projections indicating robust growth throughout the analysis period.
 

  • Factors such as rising pet ownership, heightened awareness of animal health, and advancements in veterinary care are driving the significant expansion of the market in North America.
     
  • As the pet care industry evolves, stakeholders in the North American market stand to gain, especially those who innovate and cater to the market's distinct needs.
     

These dynamics underscore North America's leading position in the companion animal arthritis market.
 

Forecasts suggest the U.S. market will grow at a CAGR of 7.1% from 2024 – 2032.
 

  • With a robust network of hospitals and veterinary clinics, pet owners in both urban and rural U.S. locales enjoy easily accessible healthcare services.
     
  • As pet ownership knowledge grows, so do the associated health costs, especially for chronic treatments like arthritis.
     

Germany is poised to lead in growth within the European companion animal arthritis market.
 

  • Boasting one of Europe's highest pet ownership rates, many German households own dogs and cats. This demographic trend lays a solid foundation for the expansion of the veterinary care industry, especially for ailments like arthritis.
     
  • Through technological advancements in diagnostics, therapeutics, and surgical techniques, Germany is elevating veterinary medicine, broadening and enhancing treatment options for conditions like arthritis in companion animals.
     

In the Asia-Pacific region, the companion animal arthritis market is projected to grow at a notable CAGR of 7.6% during the forecast period.
 

  • Countries in the Asia-Pacific are adopting cutting-edge technologies in veterinary medicine, from medications and therapeutic approaches for arthritis to advanced diagnostic tools, ensuring better access to specialized care.
     
  • Economic growth and rising disposable incomes across many Asia-Pacific nations have spurred increased spending on pet healthcare. This trend sees pet owners more inclined to invest in advanced treatments and therapies, fueling market growth.
     

Companion Animal Arthritis Market Share

The companion animal arthritis industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.
 

Companion Animal Arthritis Market Companies

Prominent players operating in the companion animal arthritis industry are as mentioned below:

  • American Regent, Inc.
  • Bayer AG (Bayer Animal Health)
  • Boehringer Ingelheim International GmbH
  • CEVA Santé Animale
  • Dechra Pharmaceuticals plc
  • Elanco Animal Health Incorporated
  • Eltech K-Laser s.r.l.
  • Medivet
  • Norbook Laboratories Ltd.
  • Nutramax Laboratories Veterinary Sciences, Inc
  • Vetoquinol SA
  • Vibrac
  • Zoetis, Inc.
     

Companion Animal Arthritis Industry News:

  • In June 2023, Zoetis launched a new monoclonal antibody therapy for treating canine osteoarthritis. This treatment aims to provide long-lasting pain relief for dogs with arthritis by targeting nerve growth factor (NGF). This introduction expanded Zoetis's product offerings.
     

The companion animal arthritis market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 to 2032 for the following segments:

Click here to Buy Section of this Report


Market, By Treatment Type

  • Medication
    • NSAIDs
    • Monoclonal antibodies
    • Other medications
  • Food supplement
  • Surgery
  • Other treatment types

Market, By Disease Type

  • Osteoarthritis
  • Rheumatoid arthritis
  • Other arthritis types

Market, By Animal Type

  • Dogs
  • Cats
  • Other animals

Market, By End-use

  • Veterinary hospitals
  • Veterinary clinics
  • Veterinary rehabilitation centers
  • Other end-users

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Netherlands
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East and Africa

 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global companion animal arthritis market was valued at around USD 3.4 billion in 2023 and will register a 7.2% CAGR, driven largely by rising pet ownership, and higher incidence rate of arthritis among dogs and cats.

The medication segment was worth USD 1.5 billion in 2023, owing to its role in symptom management, in consort with advancements in veterinary medicine, such as better diagnostics, stronger medications, and comprehensive treatment protocols.

In 2023, North America captured a 45.6% share of the global companion animal arthritis market, with anticipated strong growth driven by increasing pet ownership, greater awareness of animal health, and advancements in veterinary care.

American Regent, Inc., Bayer AG (Bayer Animal Health), Boehringer Ingelheim International GmbH, CEVA Santé Animale, Dechra Pharmaceuticals plc, Elanco Animal Health Incorporated, Eltech K-Laser s.r.l., Medivet, Norbook Laboratories Ltd., Nutramax Laboratories Veterinary Sciences, Inc, Vetoquinol SA, Vibrac, and Zoetis, Inc.

Companion Animal Arthritis Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 13
  • Tables & Figures: 343
  • Countries covered: 22
  • Pages: 196
 Download Free Sample